Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

561. Beta-blocker supplementation of standard drug treatment for schizophrenia. (Abstract)

Beta-blocker supplementation of standard drug treatment for schizophrenia. Many people with schizophrenia or similar severe mental disorders do not achieve a satisfactory treatment response with ordinary antipsychotic drug treatment. In these cases, various add-on medications are used, among them beta-adrenergic receptor antagonists (beta-blockers).To evaluate the clinical effectiveness of beta-blockers as an adjunct to antipsychotic medication in schizophrenia or similar severe mental (...) disorders.Publications in all languages were searched from the following databases: Biological Abstracts, CENTRAL of The Cochrane Library, Cochrane Schizophrenia Group's Specialised Register, EMBASE, LILACS, MEDLINE, and PsycLIT. The reference section of papers included were screened.All randomised controlled trials comparing beta-blockers with placebo as an adjunct to conventional antipsychotic medication for those with schizophrenia.Studies were selected and then data extracted, independently, by at least two

2000 Cochrane

562. Chlorpromazine versus placebo for schizophrenia. Full Text available with Trip Pro

Chlorpromazine versus placebo for schizophrenia. Chlorpromazine, formulated in the 1950s, remains a benchmark treatment for those with schizophrenia.To evaluate the effects of chlorpromazine for schizophrenia in comparison to placebo.Electronic searches of Biological Abstracts (1982-1995), The Cochrane Library (1999, Issue 2), The Cochrane Schizophrenia Group's Register (October 1999), EMBASE (1980-1995), MEDLINE (1966-1995), PsycLIT (1974-1995) were undertaken. References of all identified (...) studies were searched for further trial citations. Pharmaceutical companies and authors of trials were contacted.Randomised controlled trials relating to people with schizophrenia, and non-affective serious/chronic mental illness irrespective of mode of diagnosis evaluating chlorpromazine (any dose) versus placebo. Primary outcomes of interest were death, violent behaviours, overall improvement, relapse and satisfaction with care.Citations and, where possible, abstracts were independently inspected

2000 Cochrane

563. Psychosocial interventions for schizophrenia

Psychosocial interventions for schizophrenia Psychosocial interventions for schizophrenia Psychosocial interventions for schizophrenia NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. Psychosocial interventions for schizophrenia. University of York (...) . Effective Health Care 6(3). 2000 Authors' objectives This bulletin aims to summarise the available evidence on the effectiveness of psychosocial interventions used in the management of schizophrenia. Authors' conclusions Comprehensive care for schizophrenia involves not only drug treatments, but also the provision of ongoing support, valid information and, where appropriate, therapies or rehabilitative strategies. Individual psychoeducational interventions can decrease the risk of relapse, although

2000 Health Technology Assessment (HTA) Database.

564. Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. (Abstract)

Transcranial magnetic stimulation and auditory hallucinations in schizophrenia. 12 patients with schizophrenia and auditory hallucinations received 1 Hz transcranial magnetic stimulation of left temporoparietial cortex. In a double-blind crossover trial, active stimulation significantly reduced hallucinations relative to sham stimulation.

2000 Lancet Controlled trial quality: uncertain

565. The effectiveness of individual therapy and group therapy in the treatment of schizophrenia

The effectiveness of individual therapy and group therapy in the treatment of schizophrenia The effectiveness of individual therapy and group therapy in the treatment of schizophrenia The effectiveness of individual therapy and group therapy in the treatment of schizophrenia Hodgkinson B, Evans D, O'Donnell A, Nicholson J, Walsh K Authors' objectives To present the best available information on the use of group therapy (GT) and individual therapy (IT) in the treatment of schizophrenia (...) ', 'schizophrenia', 'psychosis', 'psychotic', 'individual therapy', 'group psychotherapy'. Bibliographies of all identified studies and review papers were searched, and key researchers and key organisations in the area were contacted. Study selection Study designs of evaluations included in the review Randomised or pseudo-randomised controlled trials (RCTs) that addressed the use or comparison of these treatment modalities. Specific interventions included in the review Group and individual therapy aimed

2000 DARE.

566. Refractory schizophrenia and atypical antipsychotics

PubMedID Other publications of related interest Kane J, Honigfeld G, Singer J, Meltzer H, the Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 1998;45:789-96. Indexing Status Subject indexing assigned by NLM MeSH Antipsychotic Agents /therapeutic use; Double-Blind Method; Drug Resistance; Evidence-Based Medicine; Humans; Prospective Studies; Randomized Controlled Trials as Topic; Research Design; Retrospective Studies; Schizophrenia /drug (...) Refractory schizophrenia and atypical antipsychotics Refractory schizophrenia and atypical antipsychotics Refractory schizophrenia and atypical antipsychotics Taylor D M, Duncan-McConnell D Authors' objectives To evaluate drug treatment for refractory schizophrenia, and to assess whether atypical antipsychotics are effective in schizophrenia unresponsive to prior antipsychotic treatment. Searching MEDLINE, PsycLIT and EMBASE were searched for English language reports that were published in full

2000 DARE.

567. Family interventions in schizophrenia and related disorders: a critical review of clinical trials

Family interventions in schizophrenia and related disorders: a critical review of clinical trials Family interventions in schizophrenia and related disorders: a critical review of clinical trials Family interventions in schizophrenia and related disorders: a critical review of clinical trials Barbato A, D'Avanzo B Authors' objectives To update evidence from studies on family intervention in schizophrenia looking carefully at methodological issues. Searching MEDLINE was searched from 1976 (...) to 1998 using the keywords 'schizophrenia' and 'family therapy' in the title, abstract and subject headings, and 'clinical trials' in publication type. Reviews on the subject, published in recent years and in English, were examined and all journals included in the list published in Evidence-based mental health (see Other Publications of Related Interest no.1) were handsearched. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were eligible

2000 DARE.

568. Patient education in schizophrenia: a review

Patient education in schizophrenia: a review Patient education in schizophrenia: a review Patient education in schizophrenia: a review Merinder L B Authors' objectives To identify and analyse methodology and results from studies of patient education in schizophrenia. Searching Searches were conducted in the following databases: MEDLINE from 1966 to 1997 using the keywords 'health education', 'patient education', 'mental disorders' and 'schizophrenia'; Excerpta Medica' from 1987 to 1997 (...) with the keywords 'health education', 'patient education', 'mental disease' and 'schizophrenia'; PsycLIT from 1974 to 1996 with the keywords 'health education', 'patient education', 'client education', 'psycho-education', 'mental disorders' and 'schizophrenia'; and CINAHL with the keywords 'health education', 'patient education', and 'schizophrenia'. Identified articles were cross-referenced. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) in patients

2000 DARE.

569. Psychosocial treatments in schizophrenia: a review of the past 20 years

Psychosocial treatments in schizophrenia: a review of the past 20 years Psychosocial treatments in schizophrenia: a review of the past 20 years Psychosocial treatments in schizophrenia: a review of the past 20 years Huxley N A, Rendall M, Sederer L Authors' objectives The authors appear to study the effectiveness of psychosocial interventions in patients with schizophrenic disorders. Searching PubMed, MEDLINE and PsycLIT were searched from 1980 to October 1999, based on the following key terms (...) Activities of Daily Living; Antipsychotic Agents /therapeutic use; Cognitive Therapy; Combined Modality Therapy; Controlled Clinical Trials as Topic; Family Therapy; Female; Forecasting; Humans; Male; Psychotherapy; Psychotherapy, Group; Psychotic Disorders /psychology /therapy; Research Design /standards /trends; Schizophrenia /diagnosis /therapy; Schizophrenic Psychology; Secondary Prevention; Social Adjustment; Treatment Outcome AccessionNumber 12000003639 Date bibliographic record published 31/01

2000 DARE.

570. The effects of psychoactive drugs and neuroleptics on language in normal subjects and schizophrenic patients: a review

discussed individually and areas of difference between the studies were listed in the text of the review. Results of the review Twelve studies of schizophrenic patients were included (at least 187 patients). There was one non-randomised controlled trial (64 patients) and 11 before-and-after studies. Neuroleptics (8 studies, 159 patients). Most of the studies showed that conventional neuroleptic treatments reduced language disorders in patients with schizophrenia. PTD and the level of aberrant utterances (...) . Bibliographic details Salome F, Boyer P, Fayol M. The effects of psychoactive drugs and neuroleptics on language in normal subjects and schizophrenic patients: a review. European Psychiatry 2000; 15(8): 461-469 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adult; Brain /physiopathology; Humans; Language; Psycholinguistics /methods; Psychotropic Drugs /pharmacology /therapeutic use; Schizophrenia /drug therapy /physiopathology; Thinking /drug effects /physiology; Verbal Behavior /drug

2000 DARE.

571. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis Geddes J, Freemantle N, Harrison P, Bebbington P Authors' objectives To develop an evidence base for recommendations on the use of atypical antipsychotics for patients (...) with schizophrenia. Searching MEDLINE, EMBASE, PsycLIT and the Cochrane Controlled Trials Register were searched to 1st December 1998 using strategies based on a combination of text and index terms. Full details of the search process are available on the BMJ website. See Web Address at end of abstract. Experts and relevant pharmaceutical companies were contacted for additional information. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) for which data

2000 DARE.

572. Cost-effectiveness analysis of case management versus a routine community care organization for patients with chronic schizophrenia

Cost-effectiveness analysis of case management versus a routine community care organization for patients with chronic schizophrenia Cost-effectiveness analysis of case management versus a routine community care organization for patients with chronic schizophrenia Cost-effectiveness analysis of case management versus a routine community care organization for patients with chronic schizophrenia Chan S, Mackenzie A, Jacobs P Record Status This is a critical abstract of an economic evaluation (...) is the case manager, who co-ordinates the care, helping to channel the patient to appropriate modes of care. Type of intervention Treatment Economic study type Cost-effectiveness analysis. Study population The study population consisted of patients with chronic schizophrenia. The inclusion criteria were suffering from schizophrenia for at least 2 years, at least 3 hospitalisations in the past 24 months before admission, requiring supervision in living skills, being unemployed for at least 3 months

2000 NHS Economic Evaluation Database.

573. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia

Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia Edgell E T, Andersen S W, Johnstone B M, Dulisse B, Revicki D, Breier A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of olanzapine, compared with risperidone, for the treatment of schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients aged between 18 and 65 years who had been diagnosed

2000 NHS Economic Evaluation Database.

574. Evidence-based nursing - treatment of people with schizophrenia

Evidence-based nursing - treatment of people with schizophrenia Evidence-based nursing - treatment of people with schizophrenia Evidence-based nursing - treatment of people with schizophrenia Hellzn O, Johanson A, Pejlert A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Hellzn O, Johanson A, Pejlert A. Evidence-based nursing - treatment (...) of people with schizophrenia. Stockholm: Swedish Council on Technology Assessment in Health Care (SBU) 1999: 71 Authors' objectives This review summarises the available evidence on the nursing care of people with schizophrenia. Authors' conclusions In Western countries, the emphasis in psychiatric care has shifted from inpatient care to outpatient services. This change means that people with schizophrenia must have access to a functioning family and support network. The scientific evidence presented

1999 Health Technology Assessment (HTA) Database.

575. Drug treatments for schizophrenia

Drug treatments for schizophrenia Drug treatments for schizophrenia Drug treatments for schizophrenia NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. Drug treatments for schizophrenia. University of York. Effective Health Care 5(6). 1999 Authors' objectives (...) This report summarises the research evidence on drug treatments for schizophrenia. Authors' conclusions Schizophrenia is one of the most common of the severe mental illnesses. Drug treatment with antipsychotics forms the mainstay of effective management, but should be used alongside a range of psychosocial interventions. The newer 'atypical' antipsychotics may be a further refinement, but not a revolution, in the care of those with schizophrenia. They may cause less adverse effects and be more acceptable

1999 Health Technology Assessment (HTA) Database.

576. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

. Rosenthal R. Combining results of independent studies. Psychol Bull 1986;85:185-93. Indexing Status Subject indexing assigned by NLM MeSH Antipsychotic Agents /adverse effects /therapeutic use; Cognition Disorders /drug therapy /psychology; Humans; Neuropsychological Tests; Randomized Controlled Trials as Topic; Schizophrenia /diagnosis /drug therapy; Schizophrenic Psychology; Treatment Outcome AccessionNumber 11999004560 Date bibliographic record published 31/03/2002 Date abstract record published 31 (...) The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis Keefe R S, Silva S G, Perkins D O, Lieberman J A Authors' objectives To critically review studies of the impact of atypical antipsychotics

1999 DARE.

577. Treatment of schizoaffective disorder and schizophrenia with mood symptoms

in the BPRS for patients (RDC-defined schizophrenia or schizoaffective disorder and high depression ratings) given haloperidol plus lithium versus haloperidol plus placebo. Treatments for schizophrenia with manic symptoms. No controlled studies were identified, although one double-blind controlled study reported a positive effect of adjunctive lithium in schizophrenic outpatients with 'anxiety' (some features of which might be described as hypomanic by some observers). Authors' conclusions Empirical data (...) affect'. In addition 'there is currently no empirical basis for the widespread long-term administration of lithium and other thymoleptics to patients with schizophrenia and schizoaffective disorders'. 'There is substantial evidence, to support trials of adjunctive antidepressants in schizophrenic and schizoaffective outpatients who have new or continued full major depressive syndromes after psychosis has stabilised'. Research: The authors highlight that there are few controlled studies of newer

1999 DARE.

578. Exercise as an adjunct treatment for schizophrenia: a review of the literature

Exercise as an adjunct treatment for schizophrenia: a review of the literature Exercise as an adjunct treatment for schizophrenia: a review of the literature Exercise as an adjunct treatment for schizophrenia: a review of the literature Faulkner G, Biddle S Authors' objectives To examine the literature investigating the use of exercise as a therapeutic adjunct treatment for schizophrenia. Searching The Social Sciences Citation Index and EMBASE via BIDS, PsycLIT, MEDLINE and SPORTDiscus were (...) . Participants included in the review Adults with schizophrenia. All patients had diagnoses of chronic schizophrenia and included male and female out-patients, in-patients, and sheltered accommodation patients. Outcomes assessed in the review The authors did not specify any inclusion or exclusion criteria relating to outcomes. Standard psychological instruments used included the Beck Depression Inventory (BDI), the Mental Health Inventory (MHI), Brief Psychotic Rating Scale (BPRS), the Nurses' Observation

1999 DARE.

579. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial

Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial Hamilton S H, Revicki D A, Edgell E T, Genduso L A, Tollefson G Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Olanzapine compared with haloperidol for treatment of schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population US-residing patients with schizophrenia who were at least 18 years

1999 NHS Economic Evaluation Database.

580. Clozapine for refractory schizophrenia: the Illinois experience

Clozapine for refractory schizophrenia: the Illinois experience Clozapine for refractory schizophrenia: the Illinois experience Clozapine for refractory schizophrenia: the Illinois experience Buckman R W, Malan R D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Clozapine for refractory schizophrenia. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study consisted of hospitalised treatment-resistant schizophrenia patients. Setting Hospital and community. The economic study was carried out in the USA. Dates to which data relate Data about the effectiveness of clozapine for refractory schizophrenia were collected between 1990 and 1995. Cost data were obtained from estimates

1999 NHS Economic Evaluation Database.